clinical trial · NCT04485949
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax·phase2·active not recruiting·n = 93
GlioblastomaIGV-001 Cell ImmunotherapyPlaceboStandard of Care (SOC): Radiation TherapySOC: Temozolomide
brief summary
The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
started
Mar 20, 2023
primary completion
Jun 1, 2026
completion
Jul 1, 2027
last updated
Feb 10, 2026
official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol